#33 – Rudy Leibel, M.D.: Finding the obesity gene and discovering leptin

Leibel's Rockefeller/Columbia clinical research center studies admitted subjects for extended inpatient stays and measured energy expenditure via both metabolic chamber (indirect calorimetry) and doubly labeled water. After 10–20% weight loss, total energy expenditure dropped by a magnitude greater than expected from the loss of metabolically active tissue alone. The excess reduction — approximately 200–300 kcal/day in larger individuals — was attributable to the leptin signal drop. Re-injecting leptin to restore pre-loss blood levels, while subjects still maintained the lower weight, fully corrected this metabolic adaptation. The effect was routed primarily through skeletal muscle inefficiency, not resting metabolic rate.

Leibel describes the metabolic chamber as the most rigorous tool available. Key equation: energy expenditure approximately 3.94 x VO2 + 1.11 x VCO2 (L/min), from Weir's derivation. Attia notes he once broke the Columbia chamber's CO2 sensor cycling vigorously inside. Validity of standard Weir coefficients under radical dietary manipulation (e.g., ketogenic diet) is an open question both discuss.

Attia underwent doubly labeled water measurement simultaneously with metabolic chamber stays and found the two methods agreed closely despite being on a ketogenic diet. Leibel notes that despite the chamber's nominal accuracy advantage, DLW's free-living validity provides important complementary data on habitual activity patterns.

Even when calories were matched to a lean animal, ob/ob mice stored proportionally more as fat. This dual phenotype (intake + partitioning) implied the defect acted centrally, not peripherally — a key conceptual pillar for the eventual leptin discovery.

Attia describes applying Leibel and Rosenbaum's metabolic chamber findings to clinical practice: checking reverse-T3 in weight-loss patients and using T3 not T4 when elevated. Leibel's leptin data and the reverse-T3 observation represent two complementary arms of the same starvation-defense system — both leptin and thyroid pathways are co-regulated components of energy homeostasis.

Leibel describes these patients as having phenotypic characteristics essentially identical to the ob/ob mouse: severe hyperphagia from infancy, infertility, and profound metabolic dysfunction. Leptin replacement effectively cures their obesity — one of the clearest examples of precision medicine in all of metabolic disease. The Amgen clinical trials that showed no efficacy in typical obesity failed precisely because the enrolled patients were not leptin-deficient; they had normal or elevated leptin with central resistance.

Coleman's parabiosis experiments from the late 1970s had already hinted at this: when an ob/ob mouse was connected to a wild-type mouse, it corrected its hyperphagia. When a db/db mouse was connected to a wild-type, the wild-type starved to death — meaning the db/db animal was over-producing a satiety signal its own brain could not receive, flooding the shared circulation. This is exactly the leptin-resistant pattern seen in most human obesity: abundant circulating leptin, absent central response. Leibel and Flier's interpretation — leptin is primarily a deficiency sensor — became the dominant model.

The energy-expenditure deficit was concentrated primarily not in resting metabolic rate but in the energy cost of low-level physical activity — muscle work at sub-maximal effort. After leptin administration, skeletal muscle became 'less efficient' (burned more ATP per unit of mechanical work), effectively restoring the pre-weight-loss expenditure. The doses used were very low — just enough to replete the falling leptin signal, not pharmacological excess. Subjects were not genetically leptin-deficient; they were normal individuals whose leptin had dropped proportionally with their lost fat mass.

Leibel's group demonstrated this using both indirect calorimetry (metabolic chamber measurements) and doubly labeled water in weight-reduced subjects. The 200–300 kcal/day delta primarily reflected the altered energy cost of non-exercise physical activity and low-level muscle contractions, not changes in basal metabolic rate or exercise efficiency at high intensities.

Leibel's experiments showed that animals with the FTO risk variants preferentially eat more of a high-fat diet versus chow. When the variants were CRISPR-deleted at fertilization, the phenotype was corrected — but post-developmental correction (after the circuitry is set) was not tested. The lab's hypothesis is that the variants affect gene(s) that regulate hypothalamic (and possibly broader CNS) circuit assembly in the fetal/neonatal period, subtly biasing the wiring toward greater food reward and/or reduced satiety signaling. fMRI studies in humans with and without the variants show characteristic differences in brain activation patterns, consistent with a structural rather than functional effect.

Wild-type pups born to the hyperinsulinemic dams showed transient body fat excess during what corresponds to adolescence in mice, reverting toward normal over time. Hypothalamic cell-type composition differed subtly from controls. A parallel set of experiments with leptin manipulation in the dam showed long-term influence on offspring metabolism, supporting the idea that early hormonal exposures can permanently alter regulatory set-points even without genetic predisposition.

The genetic map was produced by Gary Truitt in Leibel's lab using Southern blotting of crosses between Zucker and non-obese strains, generating a linkage map of the rat genome. The sucker (Zucker) gene segregated with markers on a chromosome region that was definitively not where LPL resided. Leibel notes this was initially difficult for the field to accept — people clung to biochemical observations even against genetic evidence — but it exemplified how positional cloning could settle mechanism debates.

These patients have the phenotypic hallmarks of the ob/ob mouse: severe hyperphagia beginning in infancy, morbid obesity, infertility, and metabolic dysfunction. Their distinguishing feature is measurable circulating leptin near zero. Leptin replacement normalizes appetite and weight over months. By contrast, patients with leptin receptor (OB-R / db gene equivalent) mutations cannot respond to leptin and require downstream approaches such as MC4R agonists, which are still investigational.